Beliefs about medication predict the misattribution of a common symptom as a medication side effect - Evidence from an analogue online study

Journal of Psychosomatic Research

Volumn 79, Issue 6, 2015, Pages 519-529

  Heller, Monika K ^a   Chapman, Sarah C E ^a   Horne, Rob ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adherence; Asthma; Attribution; Beliefs about medicines; Nocebo; Side effects

Indexed keywords

MONTELUKAST; ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; QUINOLINE DERIVATIVE;

ADULT; ARTICLE; ASTHMA; BELIEFS ABOUT MEDICINE QUESTIONNAIRE GENERAL; DRUG ABUSE; DRUG EFFICACY; FEMALE; HEADACHE; HEALTH BELIEF; HUMAN; MAJOR CLINICAL STUDY; MALE; ONLINE ANALYSIS; PERCEIVED TO MEDICINE SCALE; QUESTIONNAIRE; TREATMENT OUTCOME; ADVERSE DRUG REACTION; ATTITUDE TO HEALTH; EVIDENCE BASED MEDICINE; MIDDLE AGED; PERCEPTION;

ACETATES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; PERCEPTION; QUINOLINES; SURVEYS AND QUESTIONNAIRES;

EID: 84949949787     PISSN: 00223999     EISSN: 18791360     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2015.10.003     Document Type: Article

References (86)

1. Sabaté E. Adherence to Long-Term Therapies: Evidence for Action: World Health Organization 2003.
2. Boulet L.-P. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. CHEST J. 1998, 113:587-592.
3. Dimatteo M.R., Giordani P.J., Lepper H.S., Croghan T.W. Patient adherence and medical treatment outcomes: a meta-analysis. Med. Care 2002, 40:794-811.
4. Ammassari A., Murri R., Pezzotti P., Trotta M.P., Ravasio L., De Longis P., Lo Caputo S., Narciso P., Pauluzzi S., Carosi G., Nappa S., Piano P., Izzo C.M., Lichtner M., Rezza G., Monforte A.D., Ippolito G., Moroni M., Wu A.W., Antinori A., Ad I.S.G. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J. Acquir. Immune Defic. Syndr. 2001, 28:445-449.
5. Lambert M., Conus P., Eide P., Mass R., Karow A., Moritz S., Golks D., Naber D. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur. Psychiatry 2004, 19:415-422.
6. Siegel K., Schrimshaw E.W., Dean L. Symptom interpretation and medication adherence among late middle-age and older HIV-infected adults. J. Health Psychol. 1999, 4:247-257.
7. Johnson M.O., Stallworth T., Neilands T.B. The drugs or the disease? Causal attributions of symptoms held by HIV-positive adults on HAART. AIDS Behav. 2003, 7:109-117.
8. Larsen E.B., Gerlach J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr. Scand. 1996, 93:381-388.
9. Rodriguez-Monguio R., Otero M.J., Rovira J. Assessing the economic impact of adverse drug effects. PharmacoEconomics 2003, 21:623-650.
10. Vane J., Botting R. The mechanism of action of aspirin. Thromb. Res. 2003, 110:255-258.
11. Benedetti F., Lanotte M., Lopiano L., Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience 2007, 147:260-271.
12. Roscoe J.A., Hickok J.T., Morrow G.R. Patient expectations as predictor of chemotherapy-induced nausea. Ann. Behav. Med. 2000, 22:121-126.
13. Zachariae R., Paulsen K., Mehlsen M., Jensen A.B., Johansson A., von der Maase H. Anticipatory nausea: the role of individual differences related to sensory perception and autonomic reactivity. Ann. Behav. Med. 2007, 33:69-79. [Article].
14. Barsky A.J., Saintfort R., Rogers M.P., Borus J.F. Nonspecific medication side effects and the nocebo phenomenon. JAMA, J. Am. Med. Assoc. 2002, 287:622-627.
15. Faasse K., Petrie K.J. The nocebo effect: patient expectations and medication side effects. Postgrad. Med. J. 2013, 89:540-546.
16. Pogge R.C. The toxic placebo. I. Side and toxic effects reported during the administration of placebo medicine. Med. Times 1963, 91:773.
17. Rief W., Avorn J., Barsky A.J. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch. Intern. Med. 2006, 166:155-160.
18. Rief W., Nestoriuc Y., von Lilienfeld-Toal A., Dogan I., Schreiber F., Hofmann S.G., Barsky A.J., Avorn J. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials. Drug Saf. 2009, 32:1041-1056.
19. Amanzio M., Corazzini L.L., Vase L., Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009, 146:261-269.
20. Meyer F.P., Troger U., Rohl F.W. Adverse nondrug reactions: an update. Clin. Pharmacol. Ther. 1996, 60:347-352.
21. Khosla P.P., Bajaj V.K., Sharma G., Mishra K.C. Background noise in healthy volunteers: a consideration in adverse drug reaction studies. Indian J. Physiol. Pharmacol. 1992, 36:259-262.
22. Reidenberg M., Lowenthal D. Adverse nondrug reactions. N. Engl. J. Med. 1968, 279. (678-&.).
23. Horne R., Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J. Psychosom. Res. 1999, 47:555-567.
24. Horne R. Representations of Medication and Treatment: Advances in Theory and Measurement. Perceptions of Health and Illness London 1997, 155-188. UK: Harwood Academic. London, Harwood Academic Publishers, UK.
25. Horne R. Treatment perceptions and self-regulation. The Self-regulation of Health and Illness Behaviour 2003, 138-153. Routledge.
26. Horne R., Weinman J., Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol. Health 1999, 14:1-24.
27. Clifford S., Barber N., Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the necessity-concerns framework. J. Psychosom. Res. 2008, 64:41-46.
28. Horne R., Cooper V., Gellaitry G., Date H.L., Fisher M. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. JAIDS J. Acquir. Immune Defic. Syndr. 2007, 45:334-341.
29. Horne R., Chapman S.C., Parham R., Freemantle N., Forbes A., Cooper V. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the necessity-concerns framework. PLoS ONE 2013, 8.
30. Horne R., Parham R., Driscoll R., Robinson A. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm. Bowel Dis. 2009, 15:837-844.
31. Leventhal H., Nerenz D., Straus A. Self-regulation and the mechanisms for symptom appraisal. Sympt., Illn. Behav. Help-Seeking 1982, 3:55-86.
32. Leventhal H., Brissette I., Leventhal E.A. The common-sense model of self-regulation of health andillness. The Self-regulation of Health and Illness Behaviour 2003, 42-65. Routledge, London.
33. Leventhal H., Nerenz D., Straus A. Self-regulation and the mechanisms for symptom appraisal. Sympt., Illn. Behav. Help-Seeking 1982, 3:55.
34. Baumann L.J., Cameron L.D., Zimmerman R.S., Leventhal H. Illness representations and matching labels with symptoms. Health Psychol. 1989, 8:449-469.
35. Kolk A.M., Hanewald G.J., Schagen S., Gijsbers van Wijk C.M. A symptom perception approach to common physical symptoms. Soc. Sci. Med. 2003, 57:2343-2354.
36. Nestoriuc Y., Orav E.J., Liang M.H., Horne R., Barsky A.J. Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res. 2010, 62:791-799.
37. Aikens J.E., Klinkman M.S. Changes in patients' beliefs about their antidepressant during the acute phase of depression treatment. Gen. Hosp. Psychiatry 2012, 34:221-226.
38. Cooper V., Horne R. Predicting the emergence of antiretroviral therapy (ART) side effects. Invited Symposium: The Role of Psychological Variables 6th International Conference on HIV Treatment and Prevention Adherence; Miami, USA 2011.
39. Asher M.I., Montefort S., Björkstén B., Lai C.K., Strachan D.P., Weiland S.K., Williams H., Group I.P.T.S. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006, 368:733-743.
40. Stovner L.J., Zwart J.A., Hagen K., Terwindt G., Pascual J. Epidemiology of headache in Europe. Eur. J. Neurol. 2006, 13:333-345.
41. Tan K., Petrie K.J., Faasse K., Bolland M.J., Grey A. Unhelpful information about adverse drug reactions. BMJ 2014, 349:g5019.
42. Löfdahl C.-G., Reiss T.F., Leff J.A., Israel E., Noonan M.J., Finn A.F., Seidenberg B.C., Capizzi T., Kundu S., Godard P. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999, 319:87-90.
43. Wise R.A., Bartlett S.J., Brown E.D., Castro M., Cohen R., Holbrook J.T., Irvin C.G., Rand C.S., Sockrider M.M., Sugar E.A. Randomized trial of the effect of drug presentation on asthma outcomes: the American Lung Association Asthma Clinical Research Centers. J. Allergy Clin. Immunol. 2009, 124:436-444. (e8).
44. Ritter P., Lorig K., Laurent D., Matthews K. Internet versus mailed questionnaires: a randomized comparison. J. Med. Internet Res. 2004, 6.
45. Shapiro D.N., Chandler J., Mueller P.A. Using mechanical Turk to study clinical populations. Clin. Psychol. Sci. 2013, 1:213-220.
46. Buhrmester M., Kwang T., Gosling S.D. Amazon's mechanical Turk a new source of inexpensive, yet high-quality, data?. Perspect. Psychol. Sci. 2011, 6:3-5.
47. Leventhal H., Diefenbach M., Leventhal E.A. Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cogn. Ther. Res. 1992, 16:143-163.
48. Diefenbach M., Leventhal H. The common-sense model of illness representation: theoretical and practical considerations. J. Soc. Distress Homeless. 1996, 5:11-38.
49. Committee J.F., Britain RPSoG British National Formulary (BNF): Pharmaceutical Press 2012.
50. Virchow J.C., Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir. Med. 2006, 100:1952-1959.
51. Creticos P.S. Treatment options for initial maintenance therapy of persistent asthma: a review of inhaled corticosteroids and leukotriene receptor antagonists. Drugs 2003, 63(Suppl 2):1-20.
52. Diamant Z., Mantzouranis E., Bjermer L. Montelukast in the treatment of asthma and beyond. Expert. Rev. Clin. Immunol. 2009, 5:639-658.
53. Singulair (montelukast) Side Effects Centre. [cited 2012 November]; Available from: http://www.rxlist.com/singulair-side-effects-drug-center.htm.
54. Mitsikostas D.D., Mantonakis L., Chalarakis N. Nocebo in clinical trials for depression: a meta-analysis. Psychiatry Res. 2013.
55. Papadopoulos D., Mitsikostas D.D. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J. Neurol. 2012, 259:436-447.
56. Stathis P., Smpiliris M., Konitsiotis S., Mitsikostas D. Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis. Eur. J. Neurol. 2013.
57. Horne R., Faasse K., Cooper V., Diefenbach M.A., Leventhal H., Leventhal E., Petrie K.J. The perceived sensitivity to medicines (PSM) scale: an evaluation of validity and reliability. Br. J. Health Psychol. 2013, 18:18-30.
58. Mackinnon A., Jorm A.F., Christensen H., Korten A.E., Jacomb P.A., Rodgers B. A short form of the positive and negative affect schedule: evaluation of factorial validity and invariance across demographic variables in a community sample. Personal. Individ. Differ. 1999, 27:405-416.
59. Spielberger C., Gorsuch R., Lushene R. Manual for the State-Trait Inventory 1970, Consulting Psychologists, Palo Alto, California.
60. Qualtrics. Provo, UT, USA.
61. Shiyanbola O.O., Farris K.B. Concerns and beliefs about medicines and inappropriate medications: an internet-based survey on risk factors for self-reported adverse drug events among older adults. Am. J. Geriatr. Pharmacother. 2010, 8:245-257.
62. Vacha-Haase T., Thompson B. How to estimate and interpret various effect sizes. J. Couns. Psychol. 2004, 51:473.
63. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. CHEST J. 2006, 130:65S-72S.
64. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Psychology Press.
65. Bautista R.E.D., Gonzales W., Jain D. Factors associated with poor seizure control and increased side effects after switching to generic antiepileptic drugs. Epilepsy Res. 2011, 95:158-167.
66. Pennebaker J.W. The Psychology of Physical Symptoms 1982, James Pennebaker.
67. Pennebaker J.W., Skelton J.A. Psychological parameters of physical symptoms. Personal. Soc. Psychol. Bull. 1978, 4:524-530.
68. Schmidt A.J., Wolfs-Takens D.J., Oosterlaan J., van den Hout M.A. Psychological mechanisms in hypochondriasis: attention-induced physical symptoms without sensory stimulation. Psychother. Psychosom. 1994, 61:117-120.
69. Blasi Z.D., Harkness E., Ernst E., Georgiou A., Kleijnen J. Influence of context effects on health outcomes: a systematic review. Lancet 2001, 357:757-762.
70. Horne R. Patients' beliefs about treatment: the hidden determinant of treatment outcome?. J. Psychosom. Res. 1999, 47:491-495.
71. Winters W., Devriese S., Van Diest I., Nemery B., Veulemans H., Eelen P., Van de Woestijne K., Van den Bergh O. Media warnings about environmental pollution facilitate the acquisition of symptoms in response to chemical substances. Psychosom. Med. 2003, 65:332-338.
72. Watson D., Pennebaker J.W. Health complaints, stress, and distress: exploring the central role of negative affectivity. Psychol. Rev. 1989, 96:234.
73. Mora P.A., Halm E., Leventhal H., Ceric F. Elucidating the relationship between negative affectivity and symptoms: the role of illness-specific affective responses. Ann. Behav. Med. 2007, 34:77-86.
74. Van Diest I., De Peuter S., Eertmans A., Bogaerts K., Victoir A., Van den Bergh O. Negative affectivity and enhanced symptom reports: differentiating between symptoms in men and women. Soc. Sci. Med. 2005, 61:1835-1845.
75. Davis C., Ralevski E., Kennedy S.H., Neitzert C. The role of personality factors in the reporting of side effect complaints to moclobemide and placebo: a study of healthy male and female volunteers. J. Clin. Psychopharmacol. 1995, 15:347-352.
76. Foster J.M., Sanderman R., van der Molen T., Mueller T., van Sonderen E. Personality influences the reporting of side effects of inhaled corticosteroids in asthma patients. J Asthma. 2008, 45:664-669.
77. Gonzalez J.S., Penedo F.J., Llabre M.M., Durán R.E., Antoni M.H., Schneiderman N., Horne R. Physical symptoms, beliefs about medications, negative mood, and long-term HIV medication adherence. Ann. Behav. Med. 2007, 34:46-55.
78. Drici M.D., Raybaud F., De Lunardo C., Iacono P., Gustovic P. Influence of the behaviour pattern on the nocebo response of healthy volunteers. Br. J. Clin. Pharmacol. 1995, 39:204-206.
79. Uhlenhuth E.H., Alexander P.E., Dempsey G.M., Jones W., Coleman B.S., Swiontek A.M. Medication side effects in anxious patients: negative placebo responses?. J. Affect. Disord. 1998, 47:183-190.
80. Porcelli P., Cozzolongo R., Lanzilotta E., Giannuzzi V., Leandro G. Somatization symptoms or interferon-related adverse events? Alexithymia and somatization in somatic symptom reporting of patients with chronic hepatitis C. Psychother. Psychosom. 2014, 83:310-311.
81. Shiyanbola O.O., Farris K.B., Urmie J.M., Doucette W.R. Risk factors of self-reported adverse drug events among Medicare enrollees before and after Medicare part D. Pharm. Pract. (Granada) 2009, 7:218-227.
82. Paolacci G., Chandler J., Ipeirotis P.G. Running experiments on amazon mechanical Turk. Judgment and Decision making 2010, 5:411-419.
83. Powers B.J., Trinh J.V., Bosworth H.B. Can this patient read and understand written health information?. J. Am. Med. Assoc. 2010, 304:76-84.
84. Kolk A., Hanewald G., Schagen S., Gijsbers van Wijk C. Predicting medically unexplained physical symptoms and health care utilization: a symptom-perception approach. J. Psychosom. Res. 2002, 52:35-44.
85. Robbins J.M., Kirmayer L.J. Attributions of common somatic symptoms. Psychol. Med. 1991, 21:1029-1045.
86. Petrie K.J., Perry K., Broadbent E., Weinman J. A text message programme designed to modify patients' illness and treatment beliefs improves self-reported adherence to asthma preventer medication. Br. J. Health Psychol. 2012, 17:74-84.